Total Payments
$206,091
2024 Payments
$194,692
Companies
25
Transactions
180
Medicare Patients
2,340
Medicare Billing
$287,275
Payment Breakdown by Category
Other$192,920 (93.6%)
Travel$6,843 (3.3%)
Food & Beverage$3,720 (1.8%)
Research$2,549 (1.2%)
Education$59.01 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $192,920 | 8 | 93.6% |
| Travel and Lodging | $6,843 | 20 | 3.3% |
| Food and Beverage | $3,720 | 127 | 1.8% |
| Unspecified | $2,549 | 20 | 1.2% |
| Education | $59.01 | 5 | 0.0% |
Payments by Type
General
$203,543
160 transactions
Research
$2,549
20 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CIPLA USA INC. | $192,920 | 8 | $0 (2024) |
| AstraZeneca UK Limited | $3,347 | 14 | $0 (2017) |
| GlaxoSmithKline, LLC. | $1,903 | 36 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,899 | 21 | $0 (2024) |
| ALK-Abello, Inc | $1,812 | 10 | $0 (2020) |
| Regeneron Pharmaceuticals, Inc. | $1,184 | 12 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $988.22 | 9 | $0 (2018) |
| Shionogi Inc | $680.61 | 9 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $259.11 | 14 | $0 (2024) |
| PFIZER INC. | $175.82 | 10 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $194,692 | 33 | CIPLA USA INC. ($192,920) |
| 2023 | $62.01 | 3 | PFIZER INC. ($24.22) |
| 2022 | $413.04 | 13 | AstraZeneca Pharmaceuticals LP ($130.55) |
| 2021 | $260.35 | 14 | Genentech USA, Inc. ($51.10) |
| 2020 | $766.82 | 14 | Shionogi Inc ($680.61) |
| 2019 | $2,039 | 21 | ALK-Abello, Inc ($1,800) |
| 2018 | $2,877 | 37 | Regeneron Pharmaceuticals, Inc. ($1,184) |
| 2017 | $4,981 | 45 | AstraZeneca UK Limited ($3,347) |
All Payment Transactions
180 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | CIPLA USA INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $25,220.00 | General |
| 12/02/2024 | CIPLA USA INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| 10/25/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $28.83 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $100.01 | General |
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Education | In-kind items and services | $23.32 | General |
| Category: Respiratory | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Education | In-kind items and services | $21.72 | General |
| Category: Respiratory | ||||||
| 09/30/2024 | CIPLA USA INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $11,200.00 | General |
| 09/26/2024 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 09/09/2024 | CIPLA USA INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $30,990.00 | General |
| 08/29/2024 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 08/13/2024 | CIPLA USA INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $50,540.00 | General |
| 08/09/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $23.77 | General |
| Category: Respiratory | ||||||
| 07/11/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $25.20 | General |
| Category: IMMUNOLOGY | ||||||
| 07/05/2024 | CIPLA USA INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $20,320.00 | General |
| 07/02/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $20.96 | General |
| Category: Pulmonology | ||||||
| 06/28/2024 | CIPLA USA INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $16,400.00 | General |
| 06/14/2024 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 06/11/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $10.31 | General |
| Category: IMMUNOLOGY | ||||||
| 05/20/2024 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $57.74 | Research |
| Study: A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | ||||||
| 05/20/2024 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $5.87 | Research |
| Study: A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | ||||||
| 05/02/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $10.44 | General |
| Category: IMMUNOLOGY | ||||||
| 04/26/2024 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 04/25/2024 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $789.46 | Research |
| Study: A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | ||||||
| 04/25/2024 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $268.85 | Research |
| Study: A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | ||||||
| 04/25/2024 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $100.42 | Research |
| Study: A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | GlaxoSmithKline, LLC. | $1,365 | 8 |
| A Study To Evaluate The Efficacy Of Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy To Reduce Provoked Allergic Rhinitis Symptoms Using The Nasal Allergen Challenge Model | Regeneron Pharmaceuticals, Inc. | $1,184 | 12 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 618 | 9,299 | $170,654 | $66,279 |
| 2022 | 13 | 618 | 11,267 | $200,332 | $77,206 |
| 2021 | 14 | 640 | 11,838 | $206,874 | $87,147 |
| 2020 | 10 | 464 | 7,995 | $145,458 | $56,643 |
Total Patients
2,340
Total Services
40,399
Medicare Billing
$287,275
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 79 | 5,128 | $48,460 | $16,236 | 33.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 133 | 170 | $22,950 | $11,592 | 50.5% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2023 | 62 | 1,186 | $14,825 | $7,785 | 52.5% |
| 95044 | Test for allergy using skin patch | Office | 2023 | 18 | 1,471 | $18,388 | $5,471 | 29.8% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 38 | 577 | $20,195 | $5,096 | 25.2% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 36 | 405 | $10,125 | $4,683 | 46.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 37 | 42 | $7,350 | $4,201 | 57.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $7,840 | $3,774 | 48.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 39 | 39 | $7,410 | $3,344 | 45.1% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 81 | 118 | $7,670 | $2,427 | 31.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 22 | 23 | $2,346 | $634.00 | 27.0% |
| 95115 | Professional service for single injection of allergen | Office | 2023 | 13 | 77 | $2,310 | $555.43 | 24.0% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2023 | 28 | 31 | $785.85 | $480.05 | 61.1% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 90 | 5,394 | $50,973 | $17,109 | 33.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 118 | 176 | $23,760 | $11,847 | 49.9% |
| 95044 | Test for allergy using skin patch | Office | 2022 | 34 | 2,525 | $31,563 | $10,032 | 31.8% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2022 | 66 | 1,403 | $17,538 | $9,982 | 56.9% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2022 | 39 | 641 | $16,025 | $7,551 | 47.1% |
| 95117 | Professional service for multiple injections of allergen | Office | 2022 | 44 | 728 | $25,480 | $6,239 | 24.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 41 | 45 | $7,875 | $4,269 | 54.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 24 | 24 | $5,880 | $3,122 | 53.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 37 | 37 | $7,030 | $3,020 | 43.0% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 69 | 100 | $6,500 | $1,978 | 30.4% |
| 95115 | Professional service for single injection of allergen | Office | 2022 | 17 | 155 | $4,650 | $1,032 | 22.2% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 27 | 27 | $2,754 | $847.98 | 30.8% |
About Dr. John Zwetchkenbaum, M.D
Dr. John Zwetchkenbaum, M.D is a Allergy healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1124027552.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Zwetchkenbaum, M.D has received a total of $206,091 in payments from pharmaceutical and medical device companies, with $194,692 received in 2024. These payments were reported across 180 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($192,920).
As a Medicare-enrolled provider, Zwetchkenbaum has provided services to 2,340 Medicare beneficiaries, totaling 40,399 services with total Medicare billing of $287,275. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy
- Location Providence, RI
- Active Since 07/18/2005
- Last Updated 02/21/2008
- Taxonomy Code 207KA0200X
- Entity Type Individual
- NPI Number 1124027552
Products in Payments
- Dust mite (D. farinae) (Biological) $1,800
- DUPIXENT DUPILUMAB INJECTION (Biological) $1,205
- MK-7264 (Drug) $974.35
- NUCALA (Biological) $405.95
- XOLAIR (Biological) $168.03
- EUCRISA (Drug) $156.40
- CUTAQUIG (Biological) $143.07
- FASENRA (Biological) $130.35
- Epclusa (Drug) $109.95
- CINQAIR (Drug) $107.28
- Xolair (Biological) $102.29
- XOLAIR (Drug) $91.08
- TRELEGY ELLIPTA (Drug) $77.82
- RUCONEST (Biological) $48.38
- AIRSUPRA (Drug) $47.09
- SPIRIVA RESPIMAT (Drug) $38.97
- BREO (Drug) $36.71
- FASENRA (Drug) $36.25
- DUPIXENT (Biological) $24.74
- Hizentra (Biological) $23.45
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.